MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) shares dropped 2.2% during trading on Tuesday . The stock traded as low as $2.27 and last traded at $2.27. Approximately 11,370 shares traded hands during mid-day trading, an increase of 2% from the average daily volume of 11,112 shares. The stock had previously closed at $2.32.
MiNK Therapeutics Stock Performance
The business's 50 day moving average is $2.48 and its two-hundred day moving average is $2.15. The firm has a market capitalization of $76.69 million, a PE ratio of -2.91 and a beta of -0.65.
Get
MiNK Therapeutics alerts:
MiNK Therapeutics (NASDAQ:INKT – Get Rating) last posted its quarterly earnings results on Thursday, November 3rd. The company reported ($0.19) EPS for the quarter, topping analysts' consensus estimates of ($0.23) by $0.04. As a group, equities research analysts predict that MiNK Therapeutics, Inc. will post -0.84 EPS for the current year.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in MiNK Therapeutics stock. Vanguard Group Inc. acquired a new stake in MiNK Therapeutics, Inc. (NASDAQ:INKT – Get Rating) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 49,107 shares of the company's stock, valued at approximately $104,000. Vanguard Group Inc. owned 0.15% of MiNK Therapeutics at the end of the most recent quarter. 1.41% of the stock is owned by institutional investors and hedge funds.
About MiNK Therapeutics
(Get Rating)
MiNK Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. Its product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases, which is in Phase 1 clinical trials.
Read More
- Get a free copy of the StockNews.com research report on MiNK Therapeutics (INKT)
- Mobileye Expects $17.5 Billion Future For Its Driver Assist Tech
- Is Salesforce's New Rally The Beginning Of A Big Uptrend?
- Can Lockheed Martin Corporation Hit Another All-Time High in Q1?
- Marathon Digital Holdings, Inc: Slow And Steady Wins The Race
- The WD-40 Company Is Ready To Rebound, But Will It?
Receive News & Ratings for MiNK Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MiNK Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
